Novartis Terminates BioArctic Collaboration Agreement
Novartis notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025.
Story updates
09:15:42 PM UTC
SquawkNews
Novartis will discontinue its program and terminate its agreement with BioArctic. BioArctic will retain the $30M upfront payment and recognize the remaining unrecognized portion as revenue in 2026; no prior-period comparison was provided.Material DetailsContext by AI AnalystThis is a setback to one…
STOCKHOLM, Nov. 2, 2026 // -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a potential new treatment com…